xrAI - Improving Quality and Efficiency in Chest Radiograph Interpretation

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

April 21, 2020

Study Completion Date

April 21, 2020

Conditions
Pulmonary Disease
Interventions
DEVICE

Radiograph interpretation for pulmonary abnormalities

"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."

Trial Locations (1)

V6E 4B1

1QB Information Technologies Inc, Vancouver

All Listed Sponsors
collaborator

Saskatchewan Health Authority - Regina Area

OTHER

lead

1QB Information Technologies Inc.

INDUSTRY

NCT04153045 - xrAI - Improving Quality and Efficiency in Chest Radiograph Interpretation | Biotech Hunter | Biotech Hunter